<--- Back to Details
First PageDocument Content
Gene expression / Lymphoma / Quantum mirage / Gene expression profiling / Diffuse large B-cell lymphoma / Ridge / Carcinogenesis / Gene expression profiling in cancer / Biology / Medicine / Oncology
Date: 2000-02-05 16:40:10
Gene expression
Lymphoma
Quantum mirage
Gene expression profiling
Diffuse large B-cell lymphoma
Ridge
Carcinogenesis
Gene expression profiling in cancer
Biology
Medicine
Oncology

news and views sound waves with single-electron quantum waves moving over a flat surface of copper. The speaker is the STM tip held just above the surface and supplying electrons; the frequency of the sound is the energy

Add to Reading List

Source URL: llmpp.nih.gov

Download Document from Source Website

File Size: 82,56 KB

Share Document on Facebook

Similar Documents

From bloodjournal.hematologylibrary.org at Dana-Farber Cancer Institute on March 24, 2014. For personal use only: Prepublished online January 2, 2014; doi:blood

From bloodjournal.hematologylibrary.org at Dana-Farber Cancer Institute on March 24, 2014. For personal use only: Prepublished online January 2, 2014; doi:blood

DocID: 1n2p7 - View Document

reprinted from junepathology ◆ laboratory medicine ◆ laboratory management Using molecular techniques to confirm donorderived post-transplant lymphoproliferative disorder (diffuse large B-cell lymphoma of CNS)

reprinted from junepathology ◆ laboratory medicine ◆ laboratory management Using molecular techniques to confirm donorderived post-transplant lymphoproliferative disorder (diffuse large B-cell lymphoma of CNS)

DocID: 1kMDl - View Document

AACR2015 CUDC-427 Hema poster

AACR2015 CUDC-427 Hema poster

DocID: 1g9Ys - View Document

ProNAi Therapeutics Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, a Novel BCL2-Inhibitor, at ASH Annual Meeting December 09, :00 PM Eastern Standard Time ASH 2013 PLYMOUTH, Mich.--(B

ProNAi Therapeutics Reports Anti-Tumor Activity from Ongoing Phase II Clinical Study of PNT2258, a Novel BCL2-Inhibitor, at ASH Annual Meeting December 09, :00 PM Eastern Standard Time ASH 2013 PLYMOUTH, Mich.--(B

DocID: 19XdQ - View Document

Targeting their Interaction with the IP3 Receptors: New Tools to Overcome Bcl-2 Proteins-Associated Drug Resistance NOUGARÈDE Adrien ; RIMOKH Ruth ; GILLET Germain Centre de recherche en cancérologie de Lyon, U1052 INS

Targeting their Interaction with the IP3 Receptors: New Tools to Overcome Bcl-2 Proteins-Associated Drug Resistance NOUGARÈDE Adrien ; RIMOKH Ruth ; GILLET Germain Centre de recherche en cancérologie de Lyon, U1052 INS

DocID: 152Us - View Document